{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-034123","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.408580+00:00","generated_at":"2026-06-13T09:19:34.920595+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share","bullets":["Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.","GAAP net loss $21.5M ($0.54/share) includes $14.5M goodwill impairment from divestiture of Dialysis/BioSentry to Merit Medical for $100M cash.","FY2024 guidance: net sales $328-333M; gross margin 50-52%; adjusted loss per share $0.28-$0.34.","Pro forma revenue for FY23 (ex-divested businesses) was $306.3M; adjusted loss $0.43/share.","Subsequent to quarter end, used divestiture proceeds to extinguish $50M debt; cash $44.6M at May 31."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-034123","json":"https://secwatch.observer/filing/0001140361-23-034123.json","markdown":"https://secwatch.observer/filing/0001140361-23-034123.md","text":"https://secwatch.observer/filing/0001140361-23-034123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/brhc20055777_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:19:34.920595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"515be02834ea2b232893281178c2c421b87771c9","claim":"ANGIODYNAMICS INC reported fiscal fourth quarter ended May 31, 2023 results: revenue $91.1 million, net income net loss of $21.5 million, EPS GAAP loss per share of $0.54. Guidance initiated.","evidence_excerpt":"Fiscal Year 2023 Fourth Quarter Highlights • Net sales of $91.1 million increased 4.7% compared to the prior-year quarter o Med Tech net sales of $26.5 million increased 17.2% o Med Device net sales of $64.6 million increased 0.3% • Gross margin of 50.9% declined 250 basis points year over year • GAAP loss per share of $0.54, inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted earnings per share of $0.02","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal fourth quarter ended May 31, 2023"},{"label":"Revenue","value":"$91.1 million"},{"label":"Net income","value":"net loss of $21.5 million"},{"label":"EPS","value":"GAAP loss per share of $0.54"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"97bf2847a834a095fa524ee83b1f8da6dba303a0","claim":"ANGIODYNAMICS INC reported fiscal year ended May 31, 2023 results: revenue $338.8 million, EPS GAAP loss per share of $1.33. Guidance initiated.","evidence_excerpt":"Full-Year 2023 Highlights • Net sales of $338.8 million increased 7.1% year over year • Gross margin declined 100 basis points year over year to 51.4% • GAAP loss per share of $1.33 , inclusive of a goodwill impairment of $14.5 million, or $0.37 per share, in connection with the transaction announced on June 8, 2023 • Adjusted loss per share of $0.06","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036123034123/0001140361-23-034123-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended May 31, 2023"},{"label":"Revenue","value":"$338.8 million"},{"label":"EPS","value":"GAAP loss per share of $1.33"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}